FindTrial
Sign In

A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222069
Enrollment
Unknown
Registered
2013-05-02
Start date
2013-05-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Interventions

investigational material(s) Generic name etc : LY3002813 INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The study will enroll men or nonfertile women, at least 50 years of age with evidence of memory impairment on the Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR), a Mini-Mental State Examination (MMSE) 16 to 30, no history of macrohemorrhage and no more than 4 microhemorrhages on magnetic imaging resonance (MRI), and a positive amyloid scan by florbetapir. Patients with contraindication for MRI, presence of >4 microhemorrhages on MRI, history or evidence on MRI of macrohemorrhage will be excluded.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026